Carisoprodol

CHEMBL1233 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
260.3 g/mol
LogP
1.9
Phase
4

A centrally acting skeletal muscle relaxant prescribed for the short-term relief of acute musculoskeletal pain and discomfort. Its mechanism involves modulation of neuronal communication in the spinal cord and brain rather than a direct effect on muscle tissue. Because of its potential for dependence and abuse, it is classified as a controlled substance in many countries.

分子量

260.3300 g/mol

LogP

1.90

TPSA

90.70 Ų

リピンスキーの五則

適合

治療領域

作用機序

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCC(C)(COC(N)=O)COC(=O)NC(C)C

InChI

InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)

Molecular Formula

C12H24N2O4

HBD / HBA

2 / 4

回転可能結合数

9

重原子数

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A centrally acting skeletal muscle relaxant prescribed for the short-term relief of acute musculoskeletal pain and discomfort. Its mechanism involves modulation of neuronal communication in the spinal cord and brain rather than a direct effect on muscle tissue. Because of its potential for dependence and abuse, it is classified as a controlled substance in many countries.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Carisoprodol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1233. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2576. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.